![Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review - Annals of Oncology Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review - Annals of Oncology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/0b977041-7b5c-4dc8-93e4-154c8ae7f62e/gr2.jpg)
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review - Annals of Oncology
![JCM | Free Full-Text | Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies | HTML JCM | Free Full-Text | Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies | HTML](https://www.mdpi.com/jcm/jcm-07-00062/article_deploy/html/images/jcm-07-00062-g0A1.png)
JCM | Free Full-Text | Novel Indications for Bruton's Tyrosine Kinase Inhibitors, beyond Hematological Malignancies | HTML
![Action mechanism of epidermal growth factor receptor-tyrosine kinase... | Download Scientific Diagram Action mechanism of epidermal growth factor receptor-tyrosine kinase... | Download Scientific Diagram](https://www.researchgate.net/profile/Kimihiro-Shimizu/publication/233915546/figure/fig2/AS:202736541933573@1425347566317/Action-mechanism-of-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors.png)
Action mechanism of epidermal growth factor receptor-tyrosine kinase... | Download Scientific Diagram
![Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 25 Issue 9 (2018) Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 25 Issue 9 (2018)](https://erc.bioscientifica.com/view/journals/erc/25/9/images/ERC-17-0531fig1.jpeg)
Emerging multitarget tyrosine kinase inhibitors in the treatment of neuroendocrine neoplasms in: Endocrine-Related Cancer Volume 25 Issue 9 (2018)
![Frontiers | The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects | Endocrinology Frontiers | The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects | Endocrinology](https://www.frontiersin.org/files/MyHome%20Article%20Library/297357/297357_Thumb_400.jpg)
Frontiers | The Growth Hormone Receptor: Mechanism of Receptor Activation, Cell Signaling, and Physiological Aspects | Endocrinology
![Tyrosine Kinase-Inhibitor (TKI)-sensitive and-resistant Tumors and the... | Download Scientific Diagram Tyrosine Kinase-Inhibitor (TKI)-sensitive and-resistant Tumors and the... | Download Scientific Diagram](https://www.researchgate.net/publication/323259961/figure/fig1/AS:595724295225345@1519043148168/Tyrosine-Kinase-Inhibitor-TKI-sensitive-and-resistant-Tumors-and-the-Cellular.png)
Tyrosine Kinase-Inhibitor (TKI)-sensitive and-resistant Tumors and the... | Download Scientific Diagram
![Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective | Journal of Experimental & Clinical Cancer Research | Full Text Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective | Journal of Experimental & Clinical Cancer Research | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2F1756-9966-33-15/MediaObjects/13046_2014_Article_750_Fig1_HTML.jpg)
Clinical pharmacology of tyrosine kinase inhibitors becoming generic drugs: the regulatory perspective | Journal of Experimental & Clinical Cancer Research | Full Text
![PDF) 588 POSTER JNJ-26483327 is a novel multi-targeted tyrosine kinase inhibitor with cellular activity against EGFR, Her2, Src and VEGFR3 | Tarique Perera - Academia.edu PDF) 588 POSTER JNJ-26483327 is a novel multi-targeted tyrosine kinase inhibitor with cellular activity against EGFR, Her2, Src and VEGFR3 | Tarique Perera - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/47156912/mini_magick20190207-27895-1zhwt5.png?1549587263)
PDF) 588 POSTER JNJ-26483327 is a novel multi-targeted tyrosine kinase inhibitor with cellular activity against EGFR, Her2, Src and VEGFR3 | Tarique Perera - Academia.edu
![Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. - Abstract - Europe PMC Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. - Abstract - Europe PMC](https://europepmc.org/articles/PMC7140093/bin/cancers-12-00731-g002.jpg)
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy. - Abstract - Europe PMC
![The effects of angiogenesis tyrosine kinase inhibitors on hypertension.... | Download Scientific Diagram The effects of angiogenesis tyrosine kinase inhibitors on hypertension.... | Download Scientific Diagram](https://www.researchgate.net/profile/Nicola-Silvestris/publication/269520854/figure/fig1/AS:614142121619475@1523434300560/The-effects-of-angiogenesis-tyrosine-kinase-inhibitors-on-hypertension-The-block-of.png)
The effects of angiogenesis tyrosine kinase inhibitors on hypertension.... | Download Scientific Diagram
![Cancers | Free Full-Text | FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review | HTML Cancers | Free Full-Text | FDA-Approved Drugs for Hematological Malignancies—The Last Decade Review | HTML](https://www.mdpi.com/cancers/cancers-14-00087/article_deploy/html/images/cancers-14-00087-g001.png)